Press Releases Search News Category Company ReleasesCompany StatementsFinancial ReleasesProduct Releases Year None20222021202020192018201720162015201420132012201120102009200820072006 Date Title PDF Version Sep 16, 2022 Danicopan (ALXN2040) add-on to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) met primary endpoint in ALPHA Phase III trial for patients with paroxysmal nocturnal hemoglobinuria who experience clinically significant extravascular hemolysis Jun 23, 2022 ALXN1840 shows rapid and sustained improvement in copper mobilization from tissues, potentially closing treatment gaps for Wilson disease community May 05, 2022 ULTOMIRIS® (ravulizumab-cwvz) met primary endpoint in CHAMPION-NMOSD Phase III trial in adults with neuromyelitis optica spectrum disorder Apr 28, 2022 ULTOMIRIS® (ravulizumab-cwvz) approved in the US for adults with generalized myasthenia gravis Apr 06, 2022 ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks Jul 15, 2021 Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG) Jun 11, 2021 Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021 Jun 07, 2021 Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH) May 12, 2021 Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021 May 12, 2021 Alexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual Congress Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 615